IMG-7289 for Essential Thrombocythemia

Palo Alto (17 mi)

Overseen byRuben Mesa, MD

Age: 18+

Sex: Any

Travel: May be covered

Time Reimbursement: Varies

Trial Phase: Phase 2

Waitlist Available

Sponsor: The University of Texas Health Science Center at San Antonio

No Placebo Group

Prior Safety Data

Trial Summary

What is the purpose of this trial?This is a single-center, open-label investigator-initiated trial evaluating the effects of IMG-7289 administered orally once daily in patients with essential thrombocythemia.

Eligibility Criteria

Adults diagnosed with Essential Thrombocythemia who have high platelet counts despite hydroxyurea treatment, can swallow capsules, and will use contraception. Excluded are those with unresolved toxicities from past treatments, active infections including HIV/hepatitis, bleeding risks, pregnancy/breastfeeding plans within six months or current breastfeeding.

Inclusion Criteria

I can swallow pills.

I have been diagnosed with Essential Thrombocythemia according to WHO standards.

I have had fevers related to my condition.

I need treatment to lower my high platelet counts.

I am 18 years old or older.

I have leg ulcers or skin issues due to my medication.

Exclusion Criteria

I need considerable assistance and am unable to carry out any work activities.

I have had more than 3 blood transfusions in the last 6 months or any transfusion in the last 4 weeks.

I have been diagnosed with Acquired Von Willebrand's disorder.

I am currently taking MAOI medications.

I do not have any untreated or uncontrolled infections.

I have had my spleen removed.

I have tested positive for HIV or hepatitis A, B, or C.

Treatment Details

The trial is testing the oral drug IMG-7289 for patients with Essential Thrombocythemia. It's an open-label study where all participants know they're receiving the medication to see how it affects their condition.

1Treatment groups

Experimental Treatment

Group I: IMG-7289Experimental Treatment1 Intervention